Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057447 · ClinicalTrials.gov registry record · Phase 1
Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients
A Phase 1 study, sponsored by InterMune.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00057447 is a Phase 1 study that was terminated before completion, run by InterMune. The registered enrollment target is 24 participants.
The verdict
NCT00057447, a Phase 1 study, was terminated before completion, sponsored by InterMune.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL) International study with sites in the Czech Republic and Poland
Interventions
- DRUG Rituximab
- DRUG Interferon Gamma-1b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2003-03 |
| Est. Completion | 2004-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00057447
The ClinicalTrials.gov registry entry for NCT00057447 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InterMune, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT00057447 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00057447 about?
NCT00057447 is a clinical study titled "Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients". Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL) International study with sites in the Czech Republic and P...
What is the current status of trial NCT00057447?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2003-03. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00057447?
The interventions under investigation include: Rituximab (DRUG), Interferon Gamma-1b (DRUG).
Who is sponsoring clinical trial NCT00057447?
This trial is sponsored by InterMune, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.